You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Selective inhibitors of Heme Transporters as Antiparasitic Agents

    SBC: RAKTA THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION provided by applicant Neglected Tropical Diseases NTD which include helminthiasis and leishmaniasis are a group of thirteen parasitic and bacterial infections that affect over billion people Although these are devastating diseases of global concern their neglected status relative to other health concerns has resulted in a limited arsenal of therapeutic compounds for their ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Rational design of small interfering RNA for genome-wide target knockdown

    SBC: Nawgen, LLC            Topic: 172

    DESCRIPTION provided by applicant RNA interference RNAi is a small RNA guided gene silencing process within living cells The RNAi technique is widely used in both biological research and clinical applications because it has the ability to knockdown essentially any gene of interest However one major unresolved issue in RNAi studies is non specific gene silencing It is well known that in ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Broad Spectrum Antiviral for Ebola and Marburg viral Infections

    SBC: Omm Scientific, Inc            Topic: NIAID

    DESCRIPTION provided by applicant The long term goal of this project is to gain FDA approval for commercialization of a broad spectrum small molecule antiviral agent that is effective in treating Ebola virus EBOV and Marburg virus MARV These pathogens are major biothreat agents for which there are no approved therapeutic options or vaccines The developed drug will inhibit a conserved hum ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. New Assays for Expression Profiling of MicroRNAs

    SBC: Nawgen, LLC            Topic: 172

    DESCRIPTION provided by applicant MicroRNAs miRNAs are involved in many diverse biological processes and a single miRNA can modulate the expression of hundreds of gene targets Changes in miRNA expression could have profound biological impacts leading to a variety of human diseases To date most miRNA expression profiling studies have relied on microarrays or high throughput RNA sequencing ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Development of iCrystal System for Rapid Crystallization of Biological Macromolecules

    SBC: JUXTOPIA LLC            Topic: 100

    DESCRIPTION provided by applicant Biological macromolecules are the machinery of life and understanding their function helps scientists to develop new drug treatments that target specific human diseases In this regard crystallization is routinely employed for the understanding of the molecular structures and the interactions of proteins with other biological and non biological materials Desp ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Triple Re-uptake Inhibitor, SKL 10406, as a New Treatment for Alcohol Dependence

    SBC: Medication Discovery Texas, Inc            Topic: NIAAA

    DESCRIPTION provided by applicant Three medications are approved by the FDA as treatments for alcohol dependence disulfiram acamprosate and naltrexone but these are seldom prescribed due to poor efficacy or side effects Another topiramate is effective for reducing alcohol use but it causes a range of side effects that limit its tolerability Another clas of potentially effective treatment ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Green Algal Strains for Biological Control of West Nile Virus Mosquitoes

    SBC: Pond Life Technologies Limited Liability Company            Topic: NIAID

    DESCRIPTION provided by applicant West Nile virus WNV has become endemic to the US with yearly infection peaks coinciding with the activity of its mosquito vector was the worst year for WNV since with deaths and estimates of non neuroinvasive cases There is no specific treatment or vaccine so mosquito control is the only approach available Fortunately controll ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Small Molecules To Inhibit PCSK9-LDLR

    SBC: Small Molecule PPI Mimics LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This proposal is to prepare small molecules that will inhibit the protein protein interaction between a protein called PCSK and the LDLR receptor This is an extremely well validated target for reduction of andquot badandquot cholesterol LDL and therefore controlling coronary artery disease Orally available small molecules are the preferred therapeutic mo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 104

    DESCRIPTION provided by applicant Approximately of the population experiences elevated depressive symptoms Kubik et al Despite recent research suggesting that overall population mortality would be reduced by if the effects of subthreshold depression could be blocked completely the majority of individuals with elevated depressive symptoms never receive evidence based treat ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government